- Open Access
Regulation of major histocompatibility complex class II gene expression in trophoblast cells
Reproductive Biology and Endocrinologyvolume 2, Article number: 52 (2004)
Trophoblast cells are unique because they are one of the few mammalian cell types that do not express major histocompatibility complex (MHC) class II antigens, either constitutively or after exposure to IFN-γ. The absence of MHC class II antigen expression on trophoblast cells has been postulated to be one of the essential mechanisms by which the semi-allogeneic fetus evades immune rejection reactions by the maternal immune system. Consistent with this hypothesis, trophoblast cells from the placentas of women suffering from chronic inflammation of unknown etiology and spontaneous recurrent miscarriages have been reported to aberrantly express MHC class II antigens. The lack of MHC class II antigen expression on trophoblast cells is due to silencing of expression of the class II transactivator (CIITA), a transacting factor that is essential for constitutive and IFN-γ-inducible MHC class II gene transcription. Transfection of trophoblast cells with CIITA expression vectors activates both MHC class II and class Ia antigen expression, which confers on trophoblast cells both the ability to activate helper T cells, and sensitivity to lysis by cytotoxic T lymphocytes. Collectively, these studies strongly suggest that stringent silencing of CIITA (and therefore MHC class II) gene expression in trophoblast cells is critical for the prevention of immune rejection responses against the fetus by the maternal immune system. The focus of this review is to summarize studies examining the novel mechanisms by which CIITA is silenced in trophoblast cells. The elucidation of the silencing of CIITA in trophoblast cells may shed light on how the semi-allogeneic fetus evades immune rejection by the maternal immune system during pregnancy.
The successful maintenance of the semi-allogeneic mammalian fetus during pregnancy provides an apparent immunological paradox. Despite the fact that the fetus expresses proteins encoded by paternally-inherited genes, the maternal immune system does not mount an allogeneic rejection response against the fetus. However, fetal or paternal tissues transplanted into the mother at sites other than the uterus are efficiently rejected, which suggests that the pregnant uterus is an immunologically privileged site . Although the precise mechanisms underlying the lack of a rejection response against the developing fetus remain incompletely understood, trophoblast cells clearly play an essential role in the prevention of these deleterious immune reactions by several mechanisms. These include the production of multiple soluble and membrane-bound factors that inhibit lymphocytic function, and the absence on the trophoblast cell surface of major histocompatibility complex (MHC) molecules, which are required for immune recognition and activation. This review will focus on the novel mechanisms underlying the silencing of MHC class II molecule expression on trophoblast cells.
Significance of MHC class II antigens and regulation of expression
MHC class II antigens are heterodimeric cell surface glycoproteins that are essential for the activation of CD4+ helper T (TH) lymphocytes, and the subsequent initiation of antibody- and cytotoxic T lymphocyte (CTL)-based immune responses . Antigenic peptides bound to MHC class II molecules on the surface of antigen presenting cells are recognized by T cell receptors (TCR) on antigen-specific TH cells. The engagement of antigenic peptide: MHC class II complexes with TCRs on TH cells results in activation and clonal expansion of these cells, which subsequently synthesize and secrete cytokines that activate CTLs or induce the production of antibodies by B cells. Importantly, allelic differences in MHC class I and class II antigens between donor and recipient are the primary molecular basis for immunological rejection of transplanted organs, for rejection can occur when MHC class I or class II antigens on the transplanted organ differing from the recipient are recognized as "non-self" by the recipient's immune system .
Trophoblast cells are one of the few cell types that do not express MHC class II or class Ia antigens, either constitutively or after exposure to IFN-γ [3–9]. Understanding the mechanisms by which MHC class II gene expression is silenced in trophoblast cells is of intense interest because of the potential role that the lack of expression of these antigens plays in protection of the fetus from maternal immune system attack. Inappropriate MHC class II antigen expression on trophoblast cells could lead to maternal immune responses against the fetus by either stimulation of allogeneic rejection reactions against trophoblast expressing paternally-derived MHC class II antigens, or by direct presentation of fetally-derived peptides to maternal helper T cells by MHC class II-positive trophoblast cells. Consistent with these possibilities, human choriocarcinoma cell lines engineered to express MHC class II antigens were able to stimulate allogeneic T cell responses, and present antigen to antigen-specific T cells [10, 11]. Furthermore, trophoblast cells from the placentas of women suffering from chronic inflammation of unknown etiology and spontaneous recurrent miscarriages have been reported to aberrantly express MHC class II antigens [12, 13]. Collectively, these results suggest that stringent silencing of MHC class II antigen expression on trophoblast cells may be critical for the survival of the fetus during pregnancy. It is possible, however, that under certain conditions MHC class II expression is induced in the trophoblast layer following mechanical injury as described by Sims et al. , or during infection by specific pathogens. Interestingly, MHC class II expression is activated in mouse trophoblast cells treated with the histone deacetylase inhibitor trichostatin A (TSA), which is a fungal product . Thus, it is intriguing to speculate that the presence of fungi in the reproductive tract during pregnancy may result in activation of aberrant MHC class II molecule expression on trophoblast cells, which could potentially lead to the generation of a deleterious anti-fetal immune response. Surprisingly, despite the longstanding and widespread belief that aberrant expression of MHC class II antigens on trophoblast cells would lead to immune rejection of the fetus, studies that directly test this hypothesis have not been reported in the literature.
The expression of MHC class II antigens is regulated primarily at the level of transcription, in a developmental and tissue-specific manner. Constitutive MHC class II expression is restricted to professional antigen presenting cells (APC), which include dendritic cells, macrophages, thymic epithelial cells and mature B cells . MHC class II gene expression is downregulated as B cells differentiate into plasma cells . In contrast to APC, fibroblasts and cells of endothelial and epithelial origin do not express class II antigens constitutively, but do so following exposure to IFN-γ . Finally, trophoblast cells, sensory neurons and plasma cells do not express MHC class II antigens, either constitutively or after exposure to IFN-γ .
The developmental and cell-type specific pattern of MHC class II gene expression is due to differential expression of a transacting factor termed the class II transactivator (CIITA), which is considered to be the "master regulator" of MHC class II gene transcription [17, 18]. Expression of CIITA is constitutive in mature B cells and dendritic cells, and is activated by IFN-γ in fibroblasts, epithelial and endothelial cells [19–21]. The downregulation of MHC class II transcription during differentiation of B cells into plasma cells results from silencing of CIITA expression . Furthermore, the inability of trophoblast cells to transcribe MHC class II genes, even in the presence of IFN-γ, is due to silencing of CIITA expression [11, 23, 24]. Transfection of CIITA expression vectors into trophoblast cells, plasma cells, and IFN-γ-inducible cells results in constitutive cell surface expression of MHC class II molecules [11, 19–24]. Therefore, efforts to understand the cell type specific expression of MHC class II antigens have focused on delineating the mechanisms by which CIITA expression is controlled.
In addition to activating MHC class II genes, CIITA also plays an ancillary role in activating transcription of MHC class I genes in some cell types [25, 26]. Importantly, transfection of JEG-3 choriocarcinoma cells with CIITA expression vectors resulted in the activation of expression of both MHC class II molecules [11, 23, 24] and the MHC class I molecules HLA-B and HLA-C . MHC class II expression on the JEG-3 cells conferred the ability to activate antigen-specific T cells . Furthermore, JEG-3 cells expressing CIITA were sensitive to MHC-restricted lysis by cytotoxic T lymphocytes . These studies are consistent with the hypothesis that inappropriate expression of CIITA in trophoblast cells can lead to deleterious maternal immune responses against the conceptus.
Regulation of CIITA gene expression in B cells, dendritic cells and IFN-γ-inducible cells
The regulation of constitutive and IFN-γ-inducible CIITA gene expression is controlled predominantly at the level of transcription by four different promoters in human (and three in mice) that function in a cell-type specific manner [27–32]. Constitutive transcription is mediated by the type I promoter in dendritic cells and macrophages, and by the type III promoter in B and activated T cells [27–30]. The cell type specificity of the type II promoter, which is unique to humans, is currently unclear . IFN-γ-inducible CIITA transcription is controlled primarily at the type IV promoter, although the type III promoter is weakly IFN-γ-responsive in select cell types [27, 28, 31, 32]. Since the activity of CIITA promoters I and III is restricted to antigen presenting cells such as dendritic cells and B cells, investigators studying the regulation of CIITA expression in trophoblasts have concentrated on determining the mechanisms involved in silencing from the IFN-γ-responsive type IV promoter (PIV).
IFN-γ-inducible transcription from the CIITA PIV is mediated by the Janus Kinase-1/Signal Transducers and Activators of Transcription-1 (JAK-1/STAT-1) signaling pathway [Figure 1, based on [27, 28, 31–33]]. Following binding of IFN-γ to its cognate receptor, JAK-1 becomes activated, and it phosphorylates STAT-1 that is localized in the cytoplasm . Phosphorylated STAT-1 subsequently homodimerizes and translocates to the nucleus, where it activates transcription of the gene encoding a transcription factor termed interferon regulatory factor-1 (IRF-1), and a host of other genes including CIITA [27, 31–34]. The CIITA PIV contains three conserved elements, including a GAS element, which binds to activated STAT-1, an E box, which binds to the ubiquitously expressed transcription factor USF-1, and an interferon regulatory element (IRE), which binds to IRF-1 and IRF-2 [27, 31, 32]. Mutational analyses demonstrated that the GAS, E box, and IRE are all required for IFN-γ-inducible CIITA transcription [31, 32]. Consistent with these results, IFN-γ-responsive CIITA (and class II) expression is abrogated in both IRF-1 and STAT-1 deficient cells [31, 33]. Moreover, the initiation and maintenance of CIITA transcription requires sustained STAT-1 activation and threshold levels of IRF-1 . Interestingly, the transcription factor IRF-2, which is constitutively expressed and normally acts as an antagonist to IRF-1, also appears to play an essential role in IFN-γ-inducible CIITA transcription [36–38].
Recent studies indicate that chromatin structure also plays a crucial role in the transcriptional regulation of CIITA. For instance, IFN-γ-inducible CIITA transcription requires the recruitment and activity of the chromatin remodeling complex SWI/SNF to the CIITA type IV promoter . In addition, studies utilizing chromatin immunoprecipitation assays revealed that acetylation of histones H3 and H4 occurs at the CIITA PIV following exposure of fibroblast and epithelial cells to IFN-γ, and that histone acetylation is associated with successful IFN-γ-inducible CIITA transcription . It is currently unclear how histone acetyltransferases (HATs) are recruited to the CIITA promoter following IFN-γ treatment. One possibility is that STAT-1 and IRF-1 recruit the HATs CBP, pCAF, and/or 300 to the CIITA promoter, for physical interactions between STAT-1, IRF-1 and these HATs have been detected at other IFN-γ-responsive promoters . This is consistent with studies demonstrating that the increase in histone acetylation at the CIITA promoter is coincident with binding of STAT-1 in IFN-γ-treated cells . In summary, studies to date indicate that successful IFN-γ-inducible CIITA transcription requires: 1) sufficient and sustained levels of activated STAT-1, IRF-1 and IRF-2, 2) acetylation of histones at the CIITA PIV, and 3) chromatin remodeling by the SWI/SNF complex.
Regulation of CIITA gene expression in trophoblast cells
As mentioned previously, the inability of human, mouse and rat trophoblast cells to express MHC class II molecules in response to IFN-γ is due to the silencing of CIITA transcription [11, 23, 24]. Transient transfection assays demonstrated that the IFN-γ-responsive CIITA type IV promoter is functionally active in trophoblast cells, despite the fact that the endogenous CIITA gene is not expressed [11, 15, 42]. These results suggested that trophoblast cells contain the transacting DNA binding factors (STAT-1, USF-1 and IRF-1) required for IFN-γ-inducible CIITA transcription. Furthermore, these data are consistent with a model in which endogenous CIITA transcription in trophoblast cells is repressed by epigenetic mechanism(s) which maintain a closed chromatin conformation, such as promoter methylation and/or the insufficient acetylation of histones. Epigenetic repression is also consistent with the following observations: 1) neither STAT-1 nor IRF-1 are bound to the GAS and IRE of the CIITA PIV in IFN-γ-treated Jar and JEG-3 choriocarcinoma cells, and 2) the histones H3 and H4 are not acetylated at the CIITA PIV in these choriocarcinoma cells following exposure to IFN-γ [40, 42].
The CIITA type IV promoter was shown to be methylated in Jar and JEG-3 cells [11, 15, 42, 43], and in human chorionic villous trophoblast cells isolated from first trimester placentas [11, 44]. Moreover, Morris et al.  and van der Stoep et al.  reported that Jar and JEG-3 cells treated sequentially with the demethylating agent 5-azacytidine followed by IFN-γ expressed low levels of CIITA and MHC class II mRNA. These collective results led to the hypothesis that methylation of CIITA PIV is responsible for repression of IFN-γ-inducible CIITA transcription in trophoblast cells. Contrary to these studies, recent work from our laboratory demonstrated that the CIITA PIV is not methylated in primary human cytotrophoblast cells freshly isolated from term placentas, or in mouse or rat trophoblast cell lines. In addition, CIITA PIV is methylated in human 2fTGH fibrosarcoma cells, which are IFN-γ-inducible for CIITA expression . Based on the studies by van den Elsen's group  and our group , it is possible that the methylation status of CIITA PIV in human trophoblast cells may vary during different stages of pregnancy. However, the collective results from our laboratory  strongly suggest that silencing of IFN-γ-inducible CIITA transcription in trophoblast cells is not due to methylation of the CIITA PIV.
CIITA gene expression is activated in mouse trophoblast cell lines treated with the combination of IFN-γ and the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) , which indicates that HDACs are involved in silencing CIITA transcription in these cells. Furthermore, the demonstration that histones H3 and H4 are not acetylated at the CIITA PIV in Jar or JEG-3 choriocarcinoma cells after exposure to IFN-γ  suggest that the appropriate histone acetyltransferases (HATs) are either insufficiently expressed, and/or not effectively recruited to the CIITA PIV in trophoblast cells exposed to IFN-γ. Since acetylation is closely associated with an open chromatin conformation and successful transcription, these results support the concept that CIITA transcription is silenced in trophoblast cells by an epigenetic mechanism that results in a closed chromatin conformation at CIITA PIV.
As mentioned previously, the CIITA PIV is inducible by IFN-γ in transient transfection assays of trophoblast cells, which suggests that these cells contain the transacting factors (STAT-1, USF-1, IRF-1 and IRF-2) required for IFN-γ-inducible CIITA transcription. However, recent data from our laboratory demonstrate that although basal STAT-1 expression is comparable in human trophoblast versus HeLa cells, the IFN-γ induced levels of the STAT-1, IRF-1, and IRF-2 transcription factors are significantly reduced in trophoblast cells relative to HeLa or 2fTGH fibrosarcoma cells . Similar results were observed in studies of mouse trophoblast cell lines . These collective results can be interpreted at least two different ways: 1) trophoblast cells express sufficient levels of activated STAT-1, IRF-1 and IRF-2 to drive IFN-γ-inducible transcription from CIITA PIV; or 2) the chromatin structure may affect the relative amounts of STAT-1 and IRFs required to activate the CIITA PIV. In the latter instance, the endogenous PIV may require higher levels of the transcription factors for activation than the transfected, unintegrated CIITA PIV. The reduced levels of STAT-1 and IRF-1 in IFN-γ-treated trophoblast cells may also help account for: 1) why binding of these factors to the CIITA PIV has not been detected by in vivo genomic footprinting or chromatin immunoprecipitation assays of trophoblast cells [40–42], and 2) the lack of histone acetylation at the CIITA promoter in these cells, for both STAT-1 and IRF-1 recruit histone acetyltransferases (HATs) to IFN-γ-responsive promoters . Further studies are clearly required to address these issues.
A novel method for actively repressing CIITA transcription in trophoblast cells was proposed based on studies in which HeLa cells (which express CIITA in response to IFN-γ) were transfected with a Jar cell cDNA expression library, and negatively selected for MHC class II expression [47–49]. An untranslated poly A+ RNA (utRNA) was identified in choriocarcinoma cells that could repress CIITA and MHC class II expression when transfected into either HeLa cells or CH27 mouse B cells. However, the precise mechanism by which this utRNA may suppress CIITA transcription is currently unclear. Peyman  reported that this RNA contains STAT-1 (GAS) binding motifs, and proposed that by competitively binding to activated STAT-1 in the cytoplasm, the utRNA blocks STAT-1 nuclear translocation and therefore IFN-γ-inducible gene transcription. In contrast, Geirsson et al.  stated that this utRNA blocked CIITA type IV promoter activity in transient transfection assays of HeLa cells, and that the sequences of the CIITA PIV between the GAS and IRE were required for transcriptional repression. These results appear to contrast with the work of three other groups [11, 15, 42] showing that the CIITA PIV is active in transient transfection assays of trophoblast cells. In a separate study, Geirsson et al.  also showed that this trophoblast utRNA inhibited transcription from the B cell-specific CIITA type III promoter when transfected into CH27 murine B cells. The CIITA type III promoter fragment utilized in these studies does not contain a GAS, and the specific CIITA PIII sequences required for transcriptional repression were not identified in this study. Thus, further studies are necessary to elucidate the precise role that this utRNA may play in silencing CIITA transcription in trophoblast cells.
As an additional means to investigate the genetic mechanisms regulating CIITA and MHC class II gene expression in trophoblast, stable heterokaryons were generated between trophoblast and CIITA-expressing cells [15, 50]. Neither CIITA nor MHC class II molecules were expressed in stable hybrids between Jar cells and B cells, suggesting that silencing of transcription from the B cell-specific CIITA PIII is dominant in trophoblast cells . In contrast, hybrids between human Jar or JEG-3 cells and 2fTGH fibrosarcoma cells expressed both CIITA and MHC class II following exposure to IFN-γ , indicating that silencing of IFN-γ-inducible transcription from the CIITA PIV in trophoblast cells is recessive. Identical results were obtained in studies of hybrids between mouse M-11 trophoblast cells and NIH-3T3 fibroblasts . One explanation for the recessive nature of the silencing of IFN-γ-inducible CIITA transcription is that trophoblast cells express insufficient levels of essential transacting factor(s), and that higher level expression of these factors is dominant in the stable hybrids. Interestingly, the levels of IRF-1, IRF-2 and STAT-1 expression in the trophoblast/fibroblast hybrids were similar to the parental fibroblasts [44, 45], which is consistent with, but does not prove, the possibility that the failure of trophoblast cells to express CIITA may in part be due to sub-threshold levels of these DNA binding proteins. Alternatively, trophoblast cells may have deficiencies in factor(s) such as HAT(s), that plays a crucial role in controlling the chromatin structure at the CIITA type IV promoter, since histones are not acetylated at the CIITA promoter in Jar or JEG-3 cells  and TSA partially alleviates silencing of IFN-γ-inducible CIITA expression in mouse trophoblast cells . Lastly, trophoblast cells may contain a factor(s) that represses CIITA transcription, perhaps by recruiting histone deacetylases. In this scenario, expression of this putative repressor factor would be extinguished in the hybrids. It remains to be determined whether this is the case for the trophoblast-specific utRNA described by Peyman  and Geirsson et al. [48, 49].
Silencing of CIITA transcription in trophoblast cells is likely to be crucial for successful maintenance of the fetus, and recent studies suggest that the precise mechanism of silencing may be novel. Therefore, we propose the following general model to describe the mechanism by which CIITA is silenced in trophoblast (Figure 2). In the absence of IFN-γ, the CIITA PIV is associated with histone deacetylases (HDACs) and is therefore in a closed chromatin conformation in CIITA-inducible cells (fibroblasts, epithelial and endothelial cells), and trophoblast cells. The precise chromatin conformation of PIV may differ between trophoblast and the CIITA-inducible cell types because IRF-2, which is constitutively expressed at higher levels in CIITA-inducible cells compared to trophoblast cells , may be bound to the IRE in CIITA-inducible cells prior to IFN-γ treatment. Following exposure to IFN-γ, STAT-1 is activated, and IRF-1 synthesized in all of the cell types, but the levels of these factors are reduced in trophoblast cells relative to CIITA-inducible cells. These factors successfully bind to their respective elements at the CIITA PIV in fibroblasts, epithelial and endothelial cells, but fail to do so stably in trophoblast. Histone acetyltransferases (HATs) are subsequently recruited to the CIITA PIV by STAT-1 and the IRFs in CIITA-inducible cells, and HDACs are displaced, which results in further "opening" of the chromatin, and induction of CIITA transcription. In contrast, HDACs remain associated with PIV in trophoblast cells because the HATs are not recruited, and the CIITA PIV chromatin conformation remains closed.
The elucidation of the silencing of CIITA in trophoblast cells will shed light on one of the novel mechanisms by which the fetus may evade rejection by the maternal immune system during pregnancy. These studies may also have important implications for tumor immunity, for they will enable us to determine whether tumor cells that fail to express CIITA (and hence MHC class II) are usurping normal cellular mechanisms of gene regulation to evade host immune responses. Lastly, these studies may have an impact on autoimmunity and transplantation, for aberrant expression of MHC class II antigens is associated with certain autoimmune disorders, and class II antigens are one of the targets in transplant rejection.
Beer AE, Billingham RE: The embryo as a transplant. Scientific American. 1974, 230: 36-46.
Janeway C, Travers P: Immunobiology: The immune system in health and disease. 1997, Current Biology LTD. New York, NY
Chatterjee-Hasrouni S, Lala PK: MHC antigens on mouse trophoblast cells: paucity of Ia antigens despite the presence of H-2K and D. J Immunol. 1981, 127: 2070-2073.
Zuckermann FA, Head JR: Expression of MHC antigens on murine trophoblast and their modulation by interferon. J Immunol. 1986, 137: 846-853.
Feinman MA, Kliman HJ, Main EK: HLA antigen expression and induction by γ-interferon in cultured human trophoblasts. Am J Obstet Gynecol. 1987, 157: 1429-1434.
Hunt JS, Andrews GK, Wood GW: Normal trophoblasts resist induction of class I HLA. J Immunol. 1987, 138: 2481-2487.
Hunt JS, Atherton RA, Pace JL: Differential responses of rat trophoblast cells and embryonic fibroblasts to cytokines that regulate proliferation and class I MHC antigen expression. J Immunol. 1990, 145: 184-189.
Hunt JS, Fishback JL, Chumbley G, Loke YW: Identification of class I MHC mRNA in human first trimester trophoblast cells by in situ hybridization. J Immunol. 1990, 144: 4420-4425.
Peyman JA, Hammond GL: Localization of IFN-γ receptor in first trimester placenta to trophoblasts but lack of stimulation of HLA-DRA, -DRB, or invariant chain mRNA expression of IFN-γ. J Immunol. 1992, 149: 2675-2680.
Arvola M, Gustafsson E, Brunsberg U, Mattson R: Human choriocarcinoma-derived JEG-3 cells transfected with murine MHC class II Aq expression vectors present antigen to Aq-restricted murine T-cell hybridoma. J Reprod Immunol. 1999, 42: 17-30. 10.1016/S0165-0378(98)00081-3.
van den Elsen PJ, van der Stoep N, Vietor HE, Wilson L, van Zutphen M, Gobin SJP: Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-γ-inducible promoter (PIV) of CIITA. Hum Immunol. 2000, 61: 850-862. 10.1016/S0198-8859(00)00159-2.
Labarrere CA, Faulk WP: MHC class II reactivity of human villous trophoblast in chronic inflammation of unestablished etiology. Transplantation. 1990, 50: 812-816.
Athanassakis I, Aifantis Y, Makrygiannakis A, Koumantakis E, Vassiliadis S: Placental tissues from human miscarriages expresses class II HLA-DR antigens. Amer J Reprod Immunol. 1985, 34: 281-287.
Sims TN, Goes NB, Ramassar V, Urmson J, Halloran PF: In vivo class II transactivator expression in mice is induced by a non-interferon-γ mechanism in response to local injury. Transplantation. 1997, 64: 1657-1664. 10.1097/00007890-199712270-00005.
Holtz R, Choi J, Petroff MG, Piskurich JF, Murphy SP: CIITA promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol Reprod. 2003, 69: 915-924.
Glimcher LH, Kara CJ: Sequences and factors: A guide to MHC class II transcription. Annu Rev Immunol. 1992, 10: 13-49. 10.1146/annurev.iy.10.040192.000305.
Mach B, Steimle V, Martinez-Soria E, Reith W: Regulation of MHC class II genes: Lessons from a disease. Annu Rev Immunol. 1996, 14: 301-331. 10.1146/annurev.immunol.14.1.301.
Harton JA, Ting JP-Y: Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol. 2000, 20: 6185-6194. 10.1128/MCB.20.17.6185-6194.2000.
Steimle V, Siegrist C-A, Mottet A, Lisowska-Grospierre B, Mach B: Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science. 1994, 265: 106-109.
Chang C-H, Fontes JD, Peterlin M, Flavell RA: Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med. 1994, 180: 1367-1374. 10.1084/jem.180.4.1367.
Chin K-C, Mao C, Skinner C, Riley JL, Wright KL, Moreno CS, Stark GP, Boss JM, Ting JP-Y: Molecular analysis of G1B and G3A IFNγ mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii induction. Immunity. 1994, 1: 687-697. 10.1016/1074-7613(94)90039-6.
Silacci P, Mottet A, Steimle V, Reith W, Mach B: Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med. 1994, 180: 1329-1336. 10.1084/jem.180.4.1329.
Murphy SP, Tomasi TB: Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression. Mol Reprod Dev. 1998, 51: 1-12. 10.1002/(SICI)1098-2795(199809)51:1<1::AID-MRD1>3.3.CO;2-1.
Morris AC, Riley JL, Fleming WH, Boss JM: MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression. Am J Reprod Immunol. 1998, 40: 385-394.
Martin BK, Chin K-C, Olsen JC, Skinner CA, Dey A, Ozato K, Ting JP-Y: Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity. 1997, 6: 591-600. 10.1016/S1074-7613(00)80347-7.
Gobin SJ, Peijnenburg A, Keisjers V, van den Elsen PJ: Site α is crucial for two routes of IFNγ-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity. 1997, 6: 601-611. 10.1016/S1074-7613(00)80348-9.
Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B: Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997, 16: 2851-2860. 10.1093/emboj/16.10.2851.
Piskurich J, Wang Y, Linhoff MW, White LC, Ting JP-Y: Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-γ, STAT1, and TGF-β-regulated expression of the class II transactivator gene. J Immunol. 1998, 160: 233-240.
Lennon A-M, Ottone C, Rigaud G, Deaven LL, Longmire J, Fellous M, Bono R, Alcaide-Loridan C: Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics. 1997, 45: 266-273. 10.1007/s002510050202.
Holling TM, van der Stoep N, Quinten E, van den Elsen PJ: Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III. J Immunol. 2002, 168: 763-770.
Muhlethaler-Mottet A, DiBerardino W, Otten L, Mach B: Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1. Immunity. 1998, 8: 157-166. 10.1016/S1074-7613(00)80468-9.
Piskurich JF, Linhoff MW, Wang Y, Ting JP-Y: Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT-1, interferon regulatory factor 1, and transforming growth factor β. Mol Cell Biol. 1999, 19: 431-440.
Lee Y-J, Benveniste EN: Stat1α expression is involved in IFN-γ induction of the class II transactivator and class II MHC genes. J Immunol. 1996, 157: 1559-1568.
Darnell JE, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994, 264: 1415-1421.
Eason DD, Blanck G: High level class II trans-activator induction does not occur with transient activation of the IFN-γ signaling pathway. J Immunol. 2001, 166: 1041-1048.
Koenig Merediz SA, Schmidt M, Hoppe GJ, Alfken J, Meraro D, Levi BZ, Neubauer A, Wittig B: Cloning of an interferon regulatory factor 2 isoform with different regulatory ability. Nucl Acids Res. 2000, 28: 4219-4224. 10.1093/nar/28.21.4219.
Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G: Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 1999, 18: 5889-5903. 10.1038/sj.onc.1202969.
Xi H, Goodwin B, Shepherd AT, Blanck G: Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene. 2001, 20: 4219-4227. 10.1038/sj.onc.1204556.
Pattenden SG, Klose R, Karaskov E, Bremner R: Interferon-γ-induced chromatin remodeling at the CIITA locus is BRG1 dependent. EMBO J. 2002, 21: 1978-1986. 10.1093/emboj/21.8.1978.
Morris AC, Beresford GW, Mooney MR, Boss JM: Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition of methylation. Mol Cell Biol. 2002, 22: 4781-4791. 10.1128/MCB.22.13.4781-4791.2002.
Levy DE, Darnell JE: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002, 3: 651-662. 10.1038/nrm909.
Morris AC, Spangler WE, Boss JM: Methylation of class II trans-activator promoter IV: A novel mechanism of MHC class II gene control. J Immunol. 2000, 164: 4143-4149.
van den Elsen PJ, Gobin SJP, van der Stoep N, Datema G, Viëtor HE: Transcriptional control of MHC genes in fetal trophoblast cells. J Repro Immunol. 2001, 52: 129-145. 10.1016/S0165-0378(01)00115-2.
van der Stoep N, Biesta P, Quinten E, van den Elsen PJ: Lack of IFN-γ-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer. 2002, 97: 501-507. 10.1002/ijc.1623.
Choi JC, Holtz R, Petroff MG, Alfaidy N, Challis JR, Murphy SP: IFN-γ-inducible IRF-1 expression is dampened in human trophoblast cells by a proteasome-dependent mechanism.
Choi JC, Holtz R, Bangia N, Murphy SP: Post-transcriptional dampening of IFN-γ-inducible IRF-1 expression in mouse trophoblasts.
Peyman JA: Repression of major histocompatibility complex genes by a human trophoblast ribonucleic acid. Biol Reprod. 1999, 60: 23-31.
Geirsson A, Paliwal I, Lynch RJ, Bothwell ALM, Hammond GL: Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA. Transplantation. 2003, 76: 387-394. 10.1097/01.TP.0000073612.04525.46.
Geirsson A, Lynch RJ, Paliwal I, Bothwell ALM, Hammond GL: Human trophoblast noncoding RNA suppresses CIITA promoter III activity in murine B-lymphocytes. Biochem Biophys Res Comm. 2003, 301: 718-724. 10.1016/S0006-291X(03)00028-7.
Coady MA, Mandapati D, Arunachalam B, Jensen K, Maher SE, Bothwell ALM, Hammond GL: Dominant negative suppression of major histocompatibility complex genes occurs in trophoblasts. Transplantation. 1999, 67: 1461-1467. 10.1097/00007890-199906150-00012.
This work was supported by grants from the National Institutes of Health (R01 HD37464), The Buffalo Foundation, the Roswell Park Alliance, and the Roswell Park Cancer Center Support Grant P30 CA 16056. J.C. was supported by National Cancer Institute predoctoral training grant #55640201.
About this article
- Major Histocompatibility Complex Class
- Trophoblast Cell
- Transient Transfection Assay
- Maternal Immune System
- Express Major Histocompatibility Complex Class